Loading
A phase 1/2 trial of STM-416 in bladder & urothelial cancer, run by SURGE Therapeutics, now recruiting.
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer is a phase 1/2 interventional study registered as NCT05710848 by SURGE Therapeutics, with 75 participants planned, started 2023-07-11 and due to reach its primary completion in 2026-05. Interventions recorded: STM-416.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/